Clinical Trials Logo

Covid19 clinical trials

View clinical trials related to Covid19.

Filter by:
  • Available  
  • Page 1

NCT ID: NCT04745637 Available - Clinical trials for Primary Myelofibrosis (PMF)

Managed Access Programs for INC424, Ruxolitinib

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this registration is to list Managed Access Programs (MAPs) related to INC424, Ruxolitinib

NCT ID: NCT04657458 Available - Covid19 Clinical Trials

Expanded Access for Use of bmMSC-Derived Extracellular Vesicles in Patients With COVID-19 Associated ARDS

Start date: n/a
Phase:
Study type: Expanded Access

ExoFlo, Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Allograft Product, Infusion Treatment is currently being studied in Protocol DB-EF-PhaseIII-0001 in patients COVID-19 associated moderate to severe acute respiratory distress syndrome (ARDS). This expanded access protocol is an open label study intended to provide ExoFlo to critically ill patients who do not qualify for the Phase III randomized controlled trial (RCT) because they - Do not meet phase III eligibility criteria at current phase III sites. - Do meet phase III eligibility criteria but cannot access phase III sites. - Do not meet phase III eligibility criteria & cannot access phase III sites.

NCT ID: NCT04657406 Available - Covid19 Clinical Trials

Expanded Access to Zofin for Patients With COVID-19

Start date: n/a
Phase:
Study type: Expanded Access

This expanded access protocol will provide access to the investigational product Zofin for patients in outpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19, or who are judged by a healthcare provider to be at high risk of progression to moderate disease.

NCT ID: NCT04456439 Available - Clinical trials for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)

Start date: n/a
Phase:
Study type: Expanded Access

The objectives of this intermediate-size expanded access protocol are to assess the safety and efficacy of remestemcel-L in participants with MIS-C associated with COVID-19.